We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Juul
Achten
juul.achten@ndorms.ox.ac.uk
Prof
Matthew
Costa
matthew.costa@ndorms.ox.ac.uk
Stephanie
Wallis
whiteplatform@ndorms.ox.ac.uk
Injuries to the hip and thigh
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Hip fracture is one of the biggest challenges facing patients and healthcare systems. Worldwide there are 1.3 million hip fractures with more than 70,000 hip fractures in the UK every year. These figures are projected to rise to more than 6 million by 2050 worldwide.People suffering hip fracture have a 30-day mortality of 7%, a 1-year mortality of 25% and experience a permanent reduction in their health-related quality-of-life similar to that of a patient with Parkinson’s disease or multiple sclerosis.
The WHiTE platform is a framework designed to efficiently deliver multiple randomised comparisons of interventions for patients aged 60 years and over with a hip fracture. It is based upon experience derived from the planning and delivery of a related group of randomised trials of interventions for hip fracture. The purpose of the platform is to simplify the patient pathway through research in this field and capture efficiencies in the reduction of documents and clinical reporting forms duplication.
As new research questions arise, randomised comparisons will be added to the platform.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Not Specified;
You can take part if:
You may not be able to take part if:
As above, specific exclusion criteria will be assessed according to the description in the relevant appendix.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Juul
Achten
juul.achten@ndorms.ox.ac.uk
Prof
Matthew
Costa
matthew.costa@ndorms.ox.ac.uk
Stephanie
Wallis
whiteplatform@ndorms.ox.ac.uk
The study is sponsored by University of Oxford and funded by NIHR Oxford Biomedical Research Centre .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 47887
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
